TMCnet News

Research and Markets: An Essential Report on Rheumatoid Arthritis Therapeutics Market in Thailand
[February 09, 2010]

Research and Markets: An Essential Report on Rheumatoid Arthritis Therapeutics Market in Thailand

DUBLIN --(Business Wire)-- Research and Markets ( has announced the addition of Frost & Sullivan's (News - Alert) new report "Rheumatoid Arthritis Therapeutics Market in Thailand" to their offering.

This Frost & Sullivan research service titled Rheumatoid Arthritis Therapeutics Market in Thailand provides competitive structure, market analysis, and future trends. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and biologics.

DMARDS and Biologics Find Increased Application in the Treatment of Rheumatoid Arthritis in Asia Pacific While DMARDs status as the treatment of choice for rheumatoid arthritis (RA) is intact, biologics is emerging as a viable treatment option for more severe cases, and it is the focus of pharmaceutical companies clinical research. However, with high costs offsetting their outstanding efficacy, especially in developing markets, the market is open to for generic DMARDs. DMARDs affordability makes them the preferred mode of RA treatment where the costs are either reimbursed by governments or borne by the patients. The availability of generic DMARDs, coupled with their relative efficacy and low cost allows clinicians to prescribe DMARD therapies singly or in combination with other non-biological DMARDs, says the analyst of this research.

DMARDs cost-effectiveness is expected to go a long way in winning them a spot on the reimbursement lists, as governments are looking to curtail spiraling healthcare costs. Countries such as South Korea, Malaysia, and Taiwan that have comprehensive healthcare tend to promote generics and low-cost therapies, although the newer and more expensive options may be more effective. Moreover, patients are more willing to make out-of-pocket payments for inexpensive DMARDs where reimbursement is not available. DMARDs are expected to continue their market reign as usage of NSAIDs declines and growth for biologics occurs gradually. Nevertheless, their market penetration in Asia Pacific is not likely to be homogeneous due to varying government regulations regarding approval of drugs for treatment and reimbursement.

Establishing a footprint in markets that offer reimbursement is heavily dependent on getting the therapies into the reimbursement lists. In countries such as China, the Philippines, and India, which do not have extensive government reimbursement, the affordability of drugs is critical when patients have to make out-of-pocket payments. Market participants could collaborate with governments to establish the implications of the disease, in terms of potential disability and cost burden, to highlight the need for early therapy. Pharmaceutical companies could partner with governments and non-government bodies in instituting awareness programs for the disease to enable patients to seek medical attention sooner, notes the analyst. This could enhance the quality of life for patients and reduce the overall cost of treatment in the long term.

Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: Disease-modifying antirheumatic drugs (DMARDs) Nonsteroidal anti-inflammatory drugs (NSAIDs) Biologics Key Topics Covered: 1. EXECUTIVE SUMMARY Overview 2. RHEUMATOID ARTHRITIS THERAPEUTICS MARKET Market Overview - Introduction - Context for Study - Research Scope and Segmentation - Methodology - Restraints in Forecasts 3. THAILAND RHEUMATOID ARTHRITIS THERAPEUTICS MARKET Market Overview - Introduction - Measurements - Government and Industry Initiatives Market Trends and Forecasts - Insurance and Cost of Treatment Treatment and Diagnosis - Diagnostic Tests and Monitoring - Key Treaters and Patient Flow - Treatment Options - Factors Considered while Choosing a Treatment Option - Clinical Trials Competitive Analysis - Competitive Structure - Market Share Analysis - Future Trends - Challenges Faced by Physicians 4. APPENDIX For more information visit

[ Back To's Homepage ]